REG - Tristel PLC - AGM Statement

TristelAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK0767La&default-theme=true

RNS Number : 0767L  Tristel PLC  11 December 2025

TRISTEL plc

("Tristel" or the "Company")

 

AGM statement

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
will hold its Annual General Meeting at 11am today at the offices Company's
headquarters, Unit 1b Lynx Business Park, Fordham Road Snailwell, Newmarket,
Cambridgeshire, CB8 7NY.

 

Matt Sassone, Chief Executive Officer, will address the meeting with the
following update:

 

"I am pleased to report that the Company has made a strong start to the new
financial year.  Trading is in line with expectations and in the first five
months we remain firmly on target to deliver revenue growth of at least 10%
year-on-year. As in prior years, we expect a greater weighting of revenue and
profit contribution in the second half driven by winter seasonal demand across
our hospital customer base.

 

"We are seeing strong volume momentum, underpinned by solid growth in the UK
and accelerating demand across Europe, as customers increasingly adopt our
chlorine dioxide technologies and our enhanced commercial execution delivers
results.  It is pleasing to see increasing demand across Europe, given it is
the cornerstone of our international business.

 

"In the United States, we are seeing clear evidence of traction and scale-up
potential. Sales of Tristel ULT™ in the first five months of this year are
already equivalent to the full-year contribution achieved last year, and
Tristel OPH™ has made an excellent start following its launch into the
ophthalmology market. Together, these developments have resulted in a 510%
increase in total US revenue versus the prior year-to-date. The recognition of
our technology in national guidelines for the American Institute of Ultrasound
in Medicine, combined with our expanded portfolio offering in the US market,
gives us confidence in our ability to build a meaningful and sizeable business
in the world's largest healthcare market.

 

"We remain ambitious, confident and focused on delivery, and look forward to
updating shareholders further at our Interim Results in early March."

 

For further information please contact:

 

 Tristel plc                                                                Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                      www.investors.tristel.com (http://www.investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd                                                            Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Anna Dunphy    Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                              Tel: 020 7220 0500
 Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (ECM) / Louise Talbot (Sales)

 

 

 

 

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25% and the
business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMFLFSRFTLILIE



            Copyright 2019 Regulatory News Service, all rights reserved